This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

edited by Jorge D. Brioni and Michael W. Decker, 549pp, $89.95, New York, NY, John Wiley & Sons Inc, 1997.

Pierre N. Tariot, MD, Reviewer
Rochester, NY

Arch Neurol. 1997;54(12):1451.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Alzheimer disease is a common, complex disorder of late life with no known cause. There are, however, rapid advances in the understanding of its neurobiology, many of which are leading to efforts to develop mechanism-based therapies. Surveying pharmacotherapy of Alzheimer disease in a comprehensive way implies the review of issues as diverse as neuropathology, genetics, neurotransmitter physiology, pharmacology, biochemistry, phenomenology, caregiver burden, outcomes, and regulatory affairs. Since we are faced with 2 agents approved by the Food and Drug Administration now, and will likely have 10 in the next 3 years, we all need help in understanding the logic of their development and the issues that will govern their success or failure when used with our patients.

This volume takes the deliberate and necessary risk of gathering contributions from many of these different perspectives in an effort to attempt a multidisciplinary presentation. Since this is a field that is changing . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?